- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294644
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Geel, Belgium, 2440
- Investigational Site
-
Genk, Belgium, 3600
- Investigational Site
-
-
-
-
-
Besançon, France, 25030
- Investigational Site
-
Nice, France, 06000
- Investigational Site
-
Paris, France, 75007
- Investigational Site
-
Paris, France, 75116
- Investigational Site
-
Rouen, France, 76100
- Investigational Site
-
-
-
-
-
Berlin, Germany, 10827
- Investigational Site
-
Berlin, Germany, 13705
- Investigational Site
-
Bochum, Germany, 44791
- Investigational Site
-
Dresden, Germany, 01067
- Investigational Site
-
Dresden, Germany, 01097
- Investigational Site
-
Erlangen, Germany, 91054
- Investigational Site
-
Freiburg, Germany, 79104
- Investigational Site
-
Hamburg, Germany, 20146
- Investigational Site
-
Hamburg, Germany, 20354
- Investigational Site
-
Kassel, Germany, 34121
- Investigational Site
-
Lübeck, Germany, 23538
- Investigational Site
-
Mahlow, Germany, 15831
- Investigational Site
-
Monchengladbach, Germany, 41236
- Investigational Site
-
Münster, Germany, 48159
- Investigational Site
-
Regensburg, Germany, 93042
- Investigational Site
-
-
Nordrhein-Westfalen
-
Recklinghausen, Nordrhein-Westfalen, Germany, 45657
- Investigational Site
-
-
-
-
-
Roma, Italy, 00185
- Investigational Site
-
-
-
-
-
Madrid, Spain, 28043
- Investigational Site
-
-
-
-
-
Birmingham, United Kingdom, B74 2UG
- Investigational Site
-
Cardiff, United Kingdom, CF10 2GF
- Investigational Site
-
London, United Kingdom, W1G 8SF
- Investigational Site
-
Loughborough, United Kingdom, LE11 1TZ
- Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) as determined on Visit 2.
- Dissatisfaction with the submental area rated by the subject as 0, 1, 2, or 3 using the Subject Self Rating Scale (SSRS).
- Males and nonpregnant, nonlactating females between 18 and 65 years of age, inclusive on the day of randomization. Females of childbearing potential must have a negative human chorionic gonadotropin (hCG) test result within 28 days before randomization and agree to practice medically acceptable birth control during the course of the study. Medically acceptable birth control includes: surgical sterilization, hormonal contraceptives, barrier methods or an intrauterine device (IUD).
- History of stable body weight, in the judgment of the investigator, for at least 6 months before randomization. No significant change, in the judgment of the investigator, in diet or exercise practices for at least 6 months before randomization and agreement to not change diet or exercise practices during the course of the study.
- Expected to comply with and understand the visit schedule and all protocol-specified tests and procedures.
- Medically able to undergo the administration of study material determined by clinical evaluations made within 56 days before and laboratory tests obtained within 28 days before randomization for which the investigator identified no clinically significant abnormality.
- Signed informed consent obtained before any study-specific procedure is performed.
Exclusion Criteria:
- History of any intervention to treat submental fat (e.g., liposuction, surgery, or lipolytic agents) or trauma associated with the chin or neck areas, which in the judgment of the investigator may affect evaluation of safety or efficacy of treatment.
- Loose skin in the neck or chin area for which reduction in submental fat may, in the judgment of the investigator, result in an aesthetically unacceptable outcome or a score of 4 on the Skin Laxity Rating Scale (SLRS).
- Prominent platysmal bands at rest or other anatomical features that, in the judgment of the investigator, may interfere with the evaluation of submental fat or result in an aesthetically unacceptable outcome.
- Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement or cervical adenopathy) other than localized submental fat.
- Body mass index (BMI) greater than 30.
- Currently on or considering starting a weight reduction regimen.
- Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, or thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide informed consent.
- Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before randomization, or botulinum toxin injections in the neck or chin area within 6 months before randomization.
- History of sensitivity to any components of the study material or to topical or local anesthetics (e.g., lidocaine, benzocaine, or novocaine).
- Previous randomization into this study or previous treatment with ATX-101.
- Treatment with an investigational device or agent within 30 days of randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
|
Phosphate buffered saline placebo for injection
|
Experimental: Deoxycholic Acid Injection 1 mg/cm²
Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
|
Other Names:
|
Experimental: Deoxycholic Acid Injection 2 mg/cm²
Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Percentage of Participants With a Subject Self Rating Scale (SSRS) Response
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment. The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a CR-SMFRS 2-grade Response
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in CR-SMFRS Score
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in SSRS Scores
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in Submental Fat Thickness
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Submental thickness was measured using caliper devices.
|
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
The PR-SMFRS is based on the participant's response to the question "How much fat do you currently have under your chin?" answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat.
Improvement is defined as any decrease in score and worsened as any increase in score.
|
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
The PR-SMFIS assesses the impact of submental fat on self-perception of 6 characteristics related to the appearance of submental fullness as evaluated by the participant.
Each item is rated on an 11-point numeric scale from 0 to 10.
|
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in Self-rating of Attractiveness
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive. A positive change from Baseline indicates improvement. |
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Change From Baseline in Derriford Appearance Scale 24 (DAS24)
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
|
Change From Baseline in Body Image Quality of Life Inventory (BIQLI)
Time Frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Frederick Beddingfield, MD, PhD, Kythera Biopharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATX-101-10-17
- 2010-020691-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate or Severe Submental Fullness
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of
-
Kythera BiopharmaceuticalsBayerCompletedModerate or Severe Submental FullnessGermany, France, Belgium, Spain, United Kingdom
-
Kythera BiopharmaceuticalsCompletedPhase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)Moderate or Severe Submental FullnessUnited Kingdom, Canada, Australia
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
AMIpharm Co., Ltd.CompletedModerate or Severe Submental FullnessKorea, Republic of
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessAustralia, Canada, United Kingdom
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States